New Target for the Treatment of Cancer, Infectious Diseases, Cardiac Diseases, and Platelet-Associated DisordersA novel, inhibitory platelet surface protein known as TREM (Triggering Receptors in Myeloid) like Transcript (TLT-1). TLT-1 is the first inhibitory receptor discovered to reside within the TREM gene locus. Structurally, TLT-1 also possesses inhibitory domains that indicate this regulatory function. TLT-1 is highly expressed in peripheral blood platelets and may modulate many other types of myeloid cells. Additionally, the invention describes specific, human, single chain antibodies (scFvs) that recognize TLT-1.
TREM recently were discovered to modulate innate and adaptive immunity. Specifically, TREM1 amplifies the response to sepsis in innate immunity by activating neutrophils and other leukocytes; and TREM2 potentiates dendritic cell maturation in adaptive immunity.
Source:
New Target for the Treatment of Cancer, Infectious Diseases, Cardiac Diseases, and Platelet-Associated DisordersLinkback:
https://tubagbohol.mikeligalig.com/index.php?topic=65266.0
